|AHFS/Drugs.com||International Drug Names|
|Oral, topical (eye drops)|
|Metabolism||First pass elimination > 90%|
|Elimination half-life||2-4 hours (plasma)|
|Excretion||> 88% renal (as carboxybupranolol)|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||271.78298 g/mol g·mol−1|
|3D model (JSmol)|
|(what is this?)|
Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.
Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.
Adverse effects, contraindications and interactions are similar to other beta blockers.